Description

1,5-cyclooctadiene{(4S)-(-)-2-[(5R)-6-(diphenylphosphino)spiro[4.4]nona-1.6-dien-1-yl]-4,5-dihydro-4-phenyloxazole}iridiuM(I) tetrakis[3,5-bis(trifluoroMethyl)phenyl]borate is a highly specialized, chiral iridium-based organometallic complex designed for advanced catalytic applications. This compound is valued for its exceptional enantioselectivity and catalytic efficiency in asymmetric synthesis, enabling the production of high-value, optically pure intermediates. It is an essential tool for pharmaceutical R&D and fine chemical manufacturing, particularly in the synthesis of complex chiral molecules where precise stereochemical control is paramount.

Application

• Asymmetric Hydrogenation: A key catalyst for the enantioselective reduction of prochiral olefins, ketones, and imines in pharmaceutical synthesis.
• Pharmaceutical Intermediate Synthesis: Enables the production of chiral building blocks for active pharmaceutical ingredients (APIs), including those for cardiovascular, neurological, and oncological drugs.
• Fine Chemical Manufacturing: Used in the synthesis of specialty chemicals, agrochemicals, and flavors & fragrances requiring high enantiomeric purity.
• Academic and Industrial Research: A critical reagent for developing new catalytic methodologies and exploring novel reaction pathways in organometallic chemistry.
• Process Chemistry Development: Employed in the scale-up and optimization of catalytic processes for commercial production.
• Ligand Screening and Catalyst Discovery: Serves as a benchmark or precursor complex in the search for new, more efficient chiral catalysts.

Basic Information

Product Name	1,5-cyclooctadiene{(4S)-(-)-2-[(5R)-6-(diphenylphosphino)spiro[4.4]nona-1.6-dien-1-yl]-4,5-dihydro-4-phenyloxazole}iridiuM(I) tetrakis[3,5-bis(trifluoroMethyl)phenyl]borate
CAS No.	1195511-59-1
Molecular Formula	C81H60BF24IrNOP
Molecular Weight	~1750.2 g/mol (Contact for details)
Synonyms	Iridium(I) (1,5-cyclooctadiene){(4S)-(-)-2-[(5R)-6-(diphenylphosphino)spiro[4.4]nona-1.6-dien-1-yl]-4,5-dihydro-4-phenyloxazole} tetrakis[3,5-bis(trifluoromethyl)phenyl]borate; Ir-SpiroBOX Catalyst; Chiral Iridium-SpiroBOX Complex; (S,R)-Ir(SpiroBOX) BArF Salt; Asymmetric Iridium Catalyst; COD-Ir(SpiroBOX) BArF; [Ir(cod)((S,R)-SpiroBOX)]BArF
EINECS	Contact for details

Quality Control

Our high-purity organometallic catalysts are manufactured under stringent conditions to ensure batch-to-batch consistency and optimal catalytic performance. Each lot undergoes comprehensive analysis, including NMR, HPLC, and elemental analysis, to verify identity, purity, and enantiomeric excess. A detailed Certificate of Analysis (COA) is provided with every shipment, documenting all relevant specifications. We adhere to cGMP guidelines where applicable to support our clients in regulated pharmaceutical development.

Storage

Preserve in a tightly closed container, protected from light. Store under an inert atmosphere (argon or nitrogen) at -20°C or below to maintain stability and prevent decomposition. This compound is light-sensitive and easily oxidized; prolonged exposure to air, moisture, or ambient temperature should be avoided. Allow the sealed container to equilibrate to room temperature before opening to minimize condensation.

Specification

Item	Specification
Appearance	Orange to red crystalline solid or powder
Identification (NMR)	Conforms to structure
Purity (HPLC)	≥ 95%
Iridium Content	Contact for details
Moisture Content (KF)	≤ 1.0%
Solubility	Soluble in dichloromethane, toluene, THF

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.